Stockscreener 앱 받기
11.05
3.58%
-0.41
전일 마감가:
$11.46
열려 있는:
$11.53
하루 거래량:
18,380
Relative Volume:
0.49
시가총액:
$55.05M
수익:
-
순이익/손실:
$-12.49M
주가수익비율:
-3.7271
EPS:
-2.9648
순현금흐름:
$-5.93M
1주 성능:
-5.31%
1개월 성능:
-9.35%
6개월 성능:
-10.89%
1년 성능:
+42.95%
1일 변동 폭
$11.04
$11.56
1주일 범위
$10.48
$11.97
52주 변동 폭
$8.4801
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
명칭
Mink Therapeutics Inc
전화
212-994-8250
주소
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
11.05 | 55.05M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
Mink Therapeutics (INKT) Proxy filing Summary - Quartr
Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Mink Therapeutics (INKT) Q1 2025 earnings summary - Quartr
Cost of goods sold of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Understanding Momentum Shifts in (INKT) - Stock Traders Daily
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Growth Benchmark - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Value Benchmark - marketscreener.com
MiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch - TipRanks
Enterprise value to EBITDA forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
MiNK Therapeutics, Inc. Actuals & Estimates (NASDAQ:INKT) - TradingView
Price to earnings forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
Price to sales forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
INKT Forecast — Price Target — Prediction for 2027 - TradingView
MiNK Therapeutics Stockholders Back Directors, Ratify Auditor - The Globe and Mail
Total liabilities & shareholders' equities of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Form 8K Mink Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting - Stock Titan
MiNK Therapeutics (INKT) Edges Higher, Approaching Key Resistance at $12.88Liquidity Sweep - dars.gov.et
Avoiding Lag: Real-Time Signals in (INKT) Movement - Stock Traders Daily
Inventory turnover of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Diluted net income available to common stockholders of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
After tax other income/expense of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Book value per share of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
MiNK Therapeutics, Inc. Cash Flow – DUS:6Q40 - TradingView
Debt to equity ratio of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mink Therapeutics Inc (INKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mink Therapeutics Inc (INKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mink Therapeutics Inc (INKT) Institutional Confidence - TradingKey
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics (INKT) Q1 2026 earnings summary - Quartr
Mink Therapeutics (INKT) AGM 2026 Summary - Quartr
INKT: Directors and auditor elected, immune restoration strategy advanced, and global trials expanded - TradingView
Mink Therapeutics Inc (INKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mink Therapeutics Inc (INKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
Number of shareholders of MiNK Therapeutics, Inc. – FWB:6Q40 - TradingView
INKT Technical Analysis & Stock Price Forecast - Intellectia AI
MiNK Therapeutics (INKT) Rallies 1.19% as Support Holds Firm Near $11.72IV Contraction - newsline.com
INKT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor SentimentProfit Warning Alert - newsline.com
Discipline and Rules-Based Execution in INKT Response - Stock Traders Daily
Number of shareholders of MiNK Therapeutics, Inc. – LS:A40ZAV - TradingView
INKT Q1 2026 Earnings: EPS Beat on Narrower Loss, But Stock Drops 5%Quarterly Earnings Report - newsline.com
MiNK Therapeutics (INKT) Pulls Back Sharply: Support Test LoomsStrangle Setup - newsline.com
Mink Therapeutics director Barbara Ryan sells $19,141 in stock By Investing.com - Investing.com India
Insider Sell: Barbara Ryan Sells 1,500 Shares of MiNK Therapeuti - GuruFocus
Mink Therapeutics Inc (INKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):